Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 3/20 | 0.70 |
| ▸ | ZAP70 | P43403 | 4/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.59 |
| ▸ | INSR | P06213 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.57 |
| ▸ | GSK3A | P49840 | 1/20 | 0.57 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.57 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080877 | 0.83 | ULK1 (0.65) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL375362 | 0.82 | ULK1 (0.83) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL375608 | 0.82 | ULK1 (1.00) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL29900883 | 0.82 | ULK1 (1.00) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL12780549 | 0.82 | ULK1 (0.84) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL12312367 | 0.81 | ULK1 (0.81) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL12781809 | 0.81 | ULK1 (0.82) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL12780191 | 0.80 | ULK1 (0.81) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL3769118 | 0.79 | ULK1 (0.66) | ULK1ZAP70ALKINSREGFR | |
| SCHEMBL1911986 | 0.79 | ULK1 (0.75) | ULK1ZAP70ALKINSREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275413-A1 | 2,4-di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |